Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05116293 · ClinicalTrials.gov registry record
Effect of Testosterone Treatment on Drug Metabolism and Transport
A clinical trial of Transgender Persons, sponsored by University of Washington.
- Active
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT05116293 is a study of Transgender Persons that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 12 participants, below the 303-participant average among 3 other Transgender Persons trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05116293, a study of Transgender Persons, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This project will evaluate the effect of gender-affirming testosterone treatment on how other medications are processed by the body.
Conditions Studied
Interventions
- DRUG Midazolam oral solution
- DRUG Digoxin Oral Tablet
- DRUG Acetaminophen Oral Tablet
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-05-01 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05116293
The ClinicalTrials.gov registry entry for NCT05116293 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 303-participant average among 3 other Transgender Persons trials with a reported enrollment target (96% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transgender Persons appearing as the primary indexed condition, and to 3 interventions - of which Midazolam oral solution is the first listed.
NCT05116293 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT05116293 about?
NCT05116293 is a clinical study titled "Effect of Testosterone Treatment on Drug Metabolism and Transport". This project will evaluate the effect of gender-affirming testosterone treatment on how other medications are processed by the body.
What is the current status of trial NCT05116293?
This trial is currently active not recruiting. The enrollment target is 12 participants. The study started on 2021-05-01. Estimated completion is 2025-12-31.
What conditions does trial NCT05116293 study?
This clinical trial studies the following conditions: Transgender Persons.
What interventions are being tested in trial NCT05116293?
The interventions under investigation include: Midazolam oral solution (DRUG), Digoxin Oral Tablet (DRUG), Acetaminophen Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT05116293?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05116293 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transgender Persons
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.